Fmr LLC Purchases 188,368 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

FMR LLC increased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 2.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,019,746 shares of the company's stock after purchasing an additional 188,368 shares during the period. FMR LLC owned 5.57% of Denali Therapeutics worth $163,442,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in DNLI. PNC Financial Services Group Inc. boosted its position in shares of Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after acquiring an additional 885 shares during the last quarter. KBC Group NV boosted its position in shares of Denali Therapeutics by 75.8% during the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after acquiring an additional 2,731 shares during the last quarter. AlphaQuest LLC increased its position in Denali Therapeutics by 177.1% in the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock worth $142,000 after purchasing an additional 4,449 shares during the last quarter. E Fund Management Co. Ltd. raised its stake in Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after purchasing an additional 2,436 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in Denali Therapeutics by 128.8% during the fourth quarter. SG Americas Securities LLC now owns 11,003 shares of the company's stock valued at $224,000 after purchasing an additional 6,195 shares during the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on DNLI shares. Baird R W raised Denali Therapeutics to a "strong-buy" rating in a research note on Tuesday, January 7th. Robert W. Baird started coverage on shares of Denali Therapeutics in a research note on Tuesday, January 7th. They set an "outperform" rating and a $31.00 price objective for the company. Bank of America reduced their target price on shares of Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. Oppenheimer cut their price target on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. Finally, Morgan Stanley initiated coverage on shares of Denali Therapeutics in a research note on Friday, March 7th. They issued an "overweight" rating and a $33.00 price objective for the company. One research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $37.57.

Denali Therapeutics Stock Up 1.5 %

Shares of DNLI stock traded up $0.19 on Friday, hitting $12.74. The stock had a trading volume of 979,179 shares, compared to its average volume of 1,081,749. Denali Therapeutics Inc. has a one year low of $10.57 and a one year high of $33.33. The business has a 50 day moving average price of $15.78 and a 200 day moving average price of $21.43. The company has a market cap of $1.85 billion, a PE ratio of -4.62 and a beta of 1.58.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.08. Equities research analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.